ABY	affibody
ADAM10	a disintegrin and metalloproteinase domain 10
ADC	antibody drug conjugate
ADCC	antibody dependent cellular cytotoxicity
ADCN	affibody-drug conjugate nanoagent
ALCL	anaplastic large cell lymphoma
ALL	acute lymphoblastic leukemia
AML	acute myeloid leukemia
ATL	adult T-cell leukemia/lymphoma
BC	breast carcinoma/cancer
BCMA	B-cell maturation antigen
BsAb	bispecific antibody
BTN3A1	butyrophilin 3A1
BTN2A1	butyrophilin 2A1
BV	brentuximab vedotin
CAR	chimeric antigen receptor
CD	cluster of differentiation
CDC	complement dependent cytotoxicity
CDK	cyclin dependent kinase
Cet	cetuximab
CLL	Chronic lymphocytic leukemia
CR	complete response
CRBN	cereblon
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
CRC	colorectal carcinoma
CRS	cytokine release syndrome
CTL	cytotoxic T lymphocytes
CTLA4	Cytotoxic T-Lymphocyte Antigen 4
CXCR4	C-X-C motif chemokine receptor 4
Cu	cuprum
DAR	drug antibody ratio
DARPins	designed ankyrin repeat proteins
DFS	disease free survival
DLBCL	diffuse large B-cell lymphoma
DM1	mertansine/emtansine
DMAPP	dimethylallyl pyrophoshates
DNA	deoxyribonucleic acid
DOTA	1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
EBV	epstein barr virus
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
ERBB	Epidermal Growth Factor Receptor family
EXA	exatecan mesylate
Fab	fragment antigen binding
FASL	FAS ligand
FDA	food and drug administration
FISH	fluorescence situ hybridization
FKBP12	FK506 binding protein 12
GSPT1	G1 to S phase transition 1
HER2	human epidermal growth factor receptor 2
HER3	human epidermal growth factor receptor 3
HL	Hodgkin lymphoma
HTLV-1	human T-cell leukemia virus type 1
IBA	ibandronic acid
ICAM1	Intercellular adhesion molecule 1
ICI	immune checkpoint inhibitor
Ig	immunoglobulin
IFN	interferon
IHC	immunohistochemistry
IMQ	imiquimod
IPP	isopentenylpyrophosphate
LAMP1	lysosomal associated membrane protein 1
LFA1	lymphocyte function associated antigen 1
LFA3	lymphocyte function associated antigen 3
Lu	lutetium
mAbs	monoclonal antibodies
MACs	molecular glue antibody conjugates
mBC	metastatic breast carcinoma
MDS	myelodysplastic syndrome
MF	mycosis fungoide
MAPK	mitogen-activated protein kinase
MMAE	monomethyl auristatin E
MMAF	monomethyl auristatin F
Mo/MΦ	monocyte/macrophage
N-BP	aminobisphosphonate
NHL	non-Hodgkin lymphoma
NRG	neuregulin
NFkB	nuclear factor kappa B
NK	natural killer
NOTA	1,4,7-triazacyclononane-1,4,7-triacetic acid
NSCLC	non-small cell lung cancer
NSG	NOD SCID gamma
ORR	overall response rate
pAg	phosphoantigen
PBMC	peripheral blood mononuclear cells
PC	prostate carcinoma
PDAC	pancreatic adenocarcinoma
PD1	programmed cell death protein 1
PDL1	programmed cell death protein ligand 1
PDO	patient-derived organoid
PDX	patient-derived xenografts
PET	positron emission tomography
PI3K	phospho inositol 3 kinase
PFS	progression-free survival
PR	partial response
PTCL	peripheral T cell lymphoma
RAB11A	Ras-related protein Rab-11A
RIS	risedronic acid
RIT	radio immunotherapy
RLN2	relaxin 2
r/r	relapse/refractory
scFv	single-chain variable fragment
SCID	severe combined immunodeficiency
SCLC	small cell lung cancer
SD	stable disease
SMMC	succinimidyl-4-(N-maleimidomethyl cyclohexane-1carboxylate
SNX10	sorting nexin 10
SPECT	Single Photon Emission Computed Tomography
Tb	terbio
TDXd	trastuzumab deruxtecan
TDM1	trastuzumab mertansine/emtansine
TIL	tumor infiltrating lymphocyte
TNF	tumor necrosis factor
TNFRSF	tumor necrosis factor receptor superfamily
TME	tumor microenvironment
TPL	triptolide
TR	trastuzumab resistant
VC	valine-citrulline
ZA	zoledronic acid